Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. It informs about the trading window closure period around the announcement of quarterly and annual financial results. There is no financial data, report content, or detailed analysis present. The document is a regulatory compliance announcement related to insider trading rules and timing of financial results disclosure, not the financial results or report itself. The document length is short (1532 characters), and it serves as a notification to the exchanges rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-03-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges regarding a chemical leak incident at the company's manufacturing unit. It references Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content describes the incident, its impact, and compliance with regulatory disclosure requirements. There are no financial statements, earnings data, or management discussion of financial results. The document is an event disclosure under regulatory obligations rather than a financial report or meeting material. Therefore, it fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-03-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-02-16 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Listing Compliance Monitoring Team of BSE Ltd regarding a delay in disclosure of an event to the exchange. It references a prior corporate announcement submitted under SEBI regulations and explains the reason for the delay. The document is short (1314 characters) and serves as a clarification or explanation related to a regulatory disclosure event. It does not contain financial data, report content, or detailed corporate information. It is essentially a regulatory communication or compliance clarification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2026-02-13 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of unaudited financial results for the third quarter and nine months ended December 31, 2025. It references compliance with SEBI Listing Regulations, specifically Regulation 30 and 47, which pertain to disclosure and publication requirements. The document states that the financial results have been published in newspapers and encloses copies of these publications. The document itself does not contain the financial results or detailed financial data but is an announcement of the publication of these results. The document length is short (1784 characters), and it serves as a notification rather than the report itself. Therefore, according to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA).
2026-02-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges regarding the recording of an earnings conference call related to the unaudited financial results for the third quarter and nine months ended December 31, 2025. It references Regulation 30 of SEBI (LODR) Regulations 2015, which pertains to disclosure requirements. The document states that the audio recording of the earnings call has been uploaded on the company's website and provides a link. The document itself does not contain the transcript or detailed financial data, only an announcement about the availability of the recording. Given the short length (1298 characters) and the nature of the content (announcement of the recording of a call), this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Call Transcript (CT) or Earnings Release (ER).
2026-02-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.